GleamWall
中文EN

SYBX SYNLOGIC, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1527599 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-99.8%
TTM net income YoY59.2%
TTM EPS YoY79.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-511,875.0%
Net margin-291,987.5%
FCF margin-395,900.0%
EBITDA margin-507,537.5%

Returns

ROE-102.6%
ROA-49.0%
ROIC (approx.)-2,394.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets35.7%
Debt / equity0.00x
Current ratio2.80x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio17.4%
Payout ratio—
Capex / revenue175.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$8,000
R&D expense$43,000$9.15M
SG&A expense$3.49M$6.63M
Operating income-$4.01M-$40.95M
Interest expense—$0
Pretax income-$1.00M-$23.35M
Income tax$0$5,000
Net income-$1.00M-$23.36M
EBITDA-$4.01M-$40.60M
EPS (basic)-0.08-1.92
EPS (diluted)-0.08-1.92
Weighted avg. shares (diluted)12.31M12.20M
Balance sheet
Cash & equivalents$14.67M$18.86M
Short-term investments—$0
Current assets$15.40M$19.78M
PP&E, net—$0
Total assets$15.45M$19.83M
Current liabilities$3.58M$7.08M
Total liabilities$3.58M$7.08M
Shareholders' equity$11.86M$12.75M
Shares outstanding11.70M11.70M
Cash flow statement
Operating cash flow-$4.36M-$31.66M
Capital expenditure$0$14,000
Free cash flow-$4.36M-$31.67M
Investing cash flow$167,000$25.34M
Financing cash flow$0$172,000
Depreciation & amortization$0$347,000
Stock-based compensation$117,000$3.17M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.